Mylan will pay $465 million to the federal government in a settlement over one of its EpiPen scandals.
Mylan made headlines over the past year after hiking the price of its life-saving EpiPens from $100 to more than $600 for a two-pack — but that's not what it's answering for right now.
In October, Mylan was accused of shortchanging the government by knowingly misclassifying its brand name EpiPen as a generic drug. That allowed it to pay less in rebates to Medicaid.
Some say the finalized $465 million settlement isn't enough. The government estimates Mylan overcharged Medicaid $1.27 billion over 10 years. Sen. Chuck Grassley said: "The settlement is a disappointment."
The settlement allows Mylan to avoid admitting any wrongdoing.
